Perimeter Medical Imaging AI earnings date
Perimeter Medical Imaging AI (PYNKF) Q2 2026 Earnings Report
PYNKF Q2 2026 EPS Results
- Actual EPS
- -$0.02
- Consensus EPS
- -$0.02
- Beat/Miss
- Met expectations
- One Year Ago EPS
- -$0.04
PYNKF Q2 2026 Revenue Results
- Actual Revenue
- $485.39K
- Expected Revenue
- $670.00K
- Beat/Miss
- Missed by -$184.61K
- YoY Revenue Growth
- -0.55%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/20/2026
- Time
- After Close
- Conference Call
- Thursday, August 20, 2026
Perimeter Medical Imaging AI's next earnings date is estimated for November 24, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call presented a largely positive commercial and operational inflection: meaningful sequential recurring revenue growth (+31% QoQ), significant cost reductions (OpEx down 28%), improvement in net loss (down 33%), reduced operating cash burn (down 23%), FDA PMA approval for the B-Series, two initial commercial B-Series placements now performing procedures, and a CMS filing in process. Counterbalancing this are the small absolute revenue base, ongoing losses and limited cash balance (~$6.4M), early-stage commercial scale (only two B-Series in the field), and timing uncertainty driven by evolving hospital AI/IT review processes and fluid pipeline visibility. Overall, the highlights outweigh the lowlights given the regulatory milestone, initial commercial traction and improving financial trends, but execution and cash management remain critical near-term risks.
Management's guidance emphasized a continued commercial ramp balanced with tight cost control: preliminary Q2 revenue was ~$503K (31% sequential growth), operating expenses were $3.1M (down 28% YoY from $4.3M), net loss $2.6M (‑33% YoY; $0.02/share), six‑month operating cash use $5.1M (down 23% YoY) and cash of $6.4M at 6/30/26; they noted FDA PMA approval in April, two B‑Series placements (conversions from S‑Series) with commercial procedures underway, 22 total installed sites, a CMS HCPCS filing submitted in June, plans for modest OpEx increases focused on sales & marketing with new hires expected to drive revenue late‑2026/early‑2027, a ~12‑month runway from the recent raise, and the expectation that 2027 revenue will be materially higher than 2026 (management remains broadly aligned with prior 2–3× revenue growth assumptions for 2026, timing dependent on hospital AI review processes).
- Sequential Revenue Growth and Recurring RevenueRecorded revenue of approximately $503k for Q2 2026, comprised fully of recurring revenue (S-Series consumables, system leases, preventative maintenance and ESP warranty programs). This represents ~31% sequential growth over Q1 2026.
- Operating Expense ReductionQuarterly operating expenses were $3.1M for Q2 2026, a 28% decrease versus $4.3M in Q2 2025, reflecting active cost-control measures.
- Improved Net LossNet loss for Q2 2026 was $2.6M ( ~$0.02 per share), a 33% improvement from a $3.9M loss (~$0.04 per share) in Q2 2025.
- Lower Operating Cash Burn and Cash PositionCash used in operating activities for the six months ended June 30, 2026 was $5.1M, a 23% year-over-year decrease versus the comparable period in 2025. Cash on hand was $6.4M as of June 30, 2026 and management states the recent capital raise was intended to provide ~12 months runway.
- Regulatory Milestone and Initial Commercial DeploymentsReceived FDA PMA approval for the next-generation AI-enabled B-Series device in April 2026. Since approval, the company completed two B-Series placements (conversions from S-Series) and both systems are installed and performing procedures; the company announced the first commercial hospital deployment.
- Commercial Funnel Momentum and Reimbursement ProgressManagement reports a growing sales funnel composed of legacy S-Series users (upgrade candidates) and net-new users; the company submitted a CMS HCPCS filing in June (currently under review), supporting future reimbursement efforts.
- Positive Forward OutlookManagement forecasts material revenue acceleration into 2027 and remains bullish on growth trajectory. They indicated alignment with previously discussed targets (management expressed continued comfort with 2–3x revenue growth expectations, subject to timing of conversions).
PYNKF Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 24, 2026 | 2026 (Q3) | -0.03- | -0.03 | ― | ― |
| Aug 20, 2026 | 2026 (Q2) | -0.02-0.02 | -0.04 | 50.00% (+0.02) | |
| May 28, 2026 | 2026 (Q1) | ―-0.02 | -0.05 | 60.00% (+0.03) | |
| Mar 31, 2026 | 2025 (Q4) | -0.03-0.02 | -0.05 | 60.00% (+0.03) | |
| Nov 12, 2025 | 2025 (Q3) | -0.03-0.03 | -0.07 | 57.14% (+0.04) | |
| Aug 26, 2025 | 2025 (Q2) | -0.05-0.04 | -0.05 | 20.00% (+0.01) | |
| May 13, 2025 | 2025 (Q1) | ―-0.05 | -0.03 | -66.67% (-0.02) | |
| Mar 26, 2025 | 2024 (Q4) | -0.05-0.04 | -0.08 | 50.00% (+0.04) | |
| Nov 14, 2024 | 2024 (Q3) | ―-0.07 | -0.01 | -600.00% (-0.06) | |
| Aug 14, 2024 | 2024 (Q2) | -0.06-0.05 | -0.08 | 37.50% (+0.03) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


